C9orf72 and frontotemporal dementia: ,26,28 The only study looking at genetic FTD across disease stages has found that fully symptomatic MAPT and GRN mutation carriers showed smaller volumes compared to controls (12–14%), while C9orf72 expansion carriers showed reduced volumes (6%) even at a prodromal stage, reaching 16% volumetric difference when fully symptomatic.33